EIGR - Why Is Hepatitis Player Eiger BioPharma Stock Trading Lower Today? | Benzinga
Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) has discontinued the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta (CHD).
The decision is based on the Data Safety Monitoring Board (DSMB) recommendation for the study following its quarterly safety review. In a communication dated September 7, 2023, the DSMB recommended discontinuing the LIMT-2 study due to observations of four patients with hepatobiliary events that resulted ...